United States of America
Noreen Griffin is one of our Founders, our CEO and a member of our Board of Directors. Ms. Griffin was a vital part of the acquisition of our patents and therapies involving Methionine [ Met5]-enkephalin (MENK) and low-dose naltrexone (LDN). She was involved with the inventors and patent holders for over five years before deciding to join the team that formed our company. Ms. Griffin has over 25 years of industry experience, having founded and led a number of startup companies. She has played an integral role in raising multiple rounds of private and venture capital funds on behalf of clients. Ms. Griffin has served as Chief Financial Officer and Vice President of a number of small public companies over the last 10 years. In addition, Ms. Griffin has significant experience in the administration of companies in bankruptcies.
Journal of Cell Signaling [jcs] Journal of Cytokine Biology [jcb] Journal of Molecular Immunology [jmi] Rheumatology: Current Research [rcr]